Adaptive Biotechnologies (ADPT) total liabilities

Total liabilities · fiscal 2025
$287.74M

Adaptive Biotechnologies (ADPT) had total liabilities of $287.74M at the end of fiscal 2025 (December 31, 2025). That is 14.6% lower than the $336.89M of fiscal 2024. Figures as of 19 Nov 2026, 03:14 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$287.74M
Change on fiscal 2024
−14.6%
Growth, 5 years
−5.1% a year
Highest on record
$392.52Mfiscal 2022
Lowest on record
$29.94Mfiscal 2018
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Adaptive Biotechnologies total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities shrank at a compound 5.1% a year. Across the 8 fiscal years on record (2018–2025), the highest was $392.52M in fiscal 2022 and the lowest $29.94M in fiscal 2018.

History · 8 fiscal years

Total liabilities by fiscal year

Adaptive Biotechnologies total liabilities, year by year

Adaptive Biotechnologies (ADPT) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$287.74M 14.6% down
2024$336.89M 4.5% down
2023$352.86M 10.1% down
2022$392.52M 23.0% up
2021$319.24M 14.4% down
2020$373.15M 9.3% up
2019$341.26M 1,039.7% up
2018$29.94M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Adaptive Biotechnologies and comparable companies
CompanyTotal liabilitiesFiscal year
Dianthus Therapeutics DNTH$37.52M2025
MiniMed Group MMED$1.02B2026
Adaptive Biotechnologies ADPT$287.74M2025
Heartflow HTFL$58.81M2025
CRISPR Therapeutics CRSP$343.43M2025
Travere Therapeutics TVTX$490.36M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ADPT

Adaptive Biotechnologies, figure by figure

Adaptive Biotechnologies (ADPT) overview: price, valuation and scorecardAll health care companies by market value

Adaptive Biotechnologies total liabilities: questions and answers

How large are Adaptive Biotechnologies's total liabilities?

Adaptive Biotechnologies (ADPT) had total liabilities of $287.74M at the end of fiscal 2025 (December 31, 2025). That is 14.6% lower than the $336.89M of fiscal 2024.

What is the growth rate of Adaptive Biotechnologies's total liabilities?

Over the five fiscal years to 2025 total liabilities shrank at a compound 5.1% a year.

What are the highest and lowest total liabilities figures on record for Adaptive Biotechnologies?

Across the 8 fiscal years on record (2018–2025), the highest was $392.52M in fiscal 2022 and the lowest $29.94M in fiscal 2018.

How is Adaptive Biotechnologies's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Adaptive Biotechnologies it is on record here for 8 fiscal years, 2018 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Adaptive Biotechnologies (ADPT) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/ADPT/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.